Read by QxMD icon Read

Oral Oncology

A Thirumal Raj, Shankargouda Patil, Sachin C Sarode, Gargi S Sarode, Chandini Rajkumar
No abstract text is available yet for this article.
November 11, 2017: Oral Oncology
A Thirumal Raj, Shankargouda Patil, Chandini Rajkumar, Sachin Sarode
No abstract text is available yet for this article.
October 26, 2017: Oral Oncology
Arpan V Prabhu, Charles D Sturgis, Chi Lai, Jessica H Maxwell, Mihai Merzianu, Juan C Hernandez-Prera, Bibianna Purgina, Lester D R Thompson, Madalina Tuluc, Xiu Yang, Raja R Seethala, Robert L Ferris, Simion I Chiosea
OBJECTIVES: To improve margin revision, this study characterizes the number, fragmentation, and orientation of tumor bed margins (TBM) in patients with pT1-2 pN0 squamous cell carcinoma (SCC) of the oral tongue. MATERIALS AND METHODS: Pathology reports (n=346) were reviewed. TBM parameters were indexed. In Group 1 patients all margins were obtained from the glossectomy specimen and there were no TBM. In Revision Group/Group 2 (n=103), tumor bed was sampled to revise suboptimal margins identified by examination of the glossectomy specimen...
October 24, 2017: Oral Oncology
A Thirumal Raj, Shankargouda Patil
No abstract text is available yet for this article.
October 6, 2017: Oral Oncology
Piotr T Wysocki, William H Westra, David Sidransky, Mariana Brait
No abstract text is available yet for this article.
September 19, 2017: Oral Oncology
A Thirumal Raj, Shankargouda Patil, R Ranadheer, R Chandini
No abstract text is available yet for this article.
September 8, 2017: Oral Oncology
Axel Sahovaler, David H Yeh, Deric Morrison, Sandrine de Ribaupierre, Jonathan Izawa, Adam Power, Richard Inculet, Neil Parry, David A Palma, Mark Landis, Andrew Leung, Kevin Fung, S Danielle MacNeil, John Yoo, Anthony C Nichols
No abstract text is available yet for this article.
November 2017: Oral Oncology
Nosayaba Osazuwa-Peters, Matthew C Simpson, Sean T Massa, Eric Adjei Boakye, Jastin L Antisdel, Mark A Varvares
OBJECTIVES: To determine differences in oropharyngeal squamous cell carcinoma (OPSCC) incidence between 1975 and 2014 stratified by race, sex, and age. MATERIALS AND METHODS: We obtained age-adjusted OPSCC incidence rates for race and sex groups from 1975 to 2014 using the Surveillance, Epidemiology, and End Results 9 database. We defined OPSCC as cancers of the base of tongue, lingual/palatine tonsil, oropharynx, soft palate, uvula, and Waldeyer's ring. We used Joinpoint analyses to determine incidence trends for race/sex/age groupings...
November 2017: Oral Oncology
P Economopoulou, I Kotsantis, E Kyrodimos, E S Lianidou, A Psyrri
Molecular diversity and continuing evolution of metastatic tumors are not easily captured by tissue biopsies. Development of non-invasive diagnostic tools, such asanalysis of circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) and exosomes provides the opportunity to assess a blood sample in order to monitor tumor change and extract molecular information from cancers at a given time. "Liquid biopsy", which refers to molecular analysis of tumor's genetic features based on circulating genetic material in the peripheral blood, is already used to monitor disease response and track mechanisms of drug resistance in solid tumors...
November 2017: Oral Oncology
Daniel L Faden, Sean Thomas, Paul G Cantalupo, Nishant Agrawal, Jeffrey Myers, Joseph DeRisi
OBJECTIVES: The mutagenic processes underlying head and neck squamous cell carcinoma (HNSCC) are poorly understood. Pan-cancer mutational signature analyses have identified a signature for APOBEC, a cytosine deaminase, in a subset of cancers, including HNSCC. The role of APOBEC activity in HNSCC remains poorly understood. Therefore, we sought to determine the role of APOBEC in HNSCC pathogenesis. MATERIAL AND METHODS: Utilizing bioinformatic approaches we explored the role of APOBEC mediated mutations in tumor exomes, transcriptomes and germline exomes from 511HNSCC patients in the TCGA...
November 2017: Oral Oncology
Katrin Håkansson, Jacob H Rasmussen, Gregers B Rasmussen, Jeppe Friborg, Thomas A Gerds, Barbara Malene Fischer, Flemming L Andersen, Søren M Bentzen, Lena Specht, Ivan R Vogelius
OBJECTIVES: The objective of this work was to develop a tool for decision support, providing simultaneous predictions of the risk of loco-regional failure (LRF) and distant metastasis (DM) after definitive treatment for head-and-neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: Retrospective data for 560HNSCC patients were used to generate a multi-endpoint model, combining three cause-specific Cox models (LRF, DM and death with no evidence of disease (death NED))...
November 2017: Oral Oncology
Petr Szturz, Marie Budíková, Jan B Vermorken, Ivana Horová, Břetislav Gál, Eric Raymond, Armand de Gramont, Sandrine Faivre
OBJECTIVES: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated. METHODS: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN...
November 2017: Oral Oncology
Yong Hoon Cha, Eunae Sandra Cho, Hee Eun Kang, Jaemin Ko, Woong Nam, Hyung Jun Kim, Nam Hee Kim, Hyun Sil Kim, In-Ho Cha, Jong In Yook
OBJECTIVES: Odontogenic keratocyst (OKC), also known as keratocystic odontogenic tumor (KCOT), has clinical significance due to its high incidence as well as high recurrence rate after surgical enucleation. Current clinical management for OCK is entirely dependent on surgical approach. While various genetic alterations, such as PTCH1 mutation and loss of heterozygosity in tumor suppressor genes, have been reported, the molecular background of OKC is not well-understood. Although recent identification of BRAF V600E mutation and subsequent activation of mitogen-activated protein kinase (MAPK) pathway in ameloblastoma and odontogenic tumors provide additional options with targeted therapeutics, the molecular background of OKC is not well understood...
November 2017: Oral Oncology
Jeffrey Shevach, Adam Bossert, Richard L Bakst, Jerry Liu, Krzysztof Misiukiewicz, Jessica Beyda, Brett A Miles, Eric Genden, Marshall R Posner, Vishal Gupta
OBJECTIVES: To determine the prognostic utility of pathologic extracapsular extension (ECE) in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC). MATERIALS AND METHODS: Retrospective analysis was performed on patients who underwent surgery for primary HPV-related OPSCC and received adjuvant radiotherapy (RT) between 2006 and 2015. Locoregional control (LRC), distant control (DC), progression-free survival (PFS) and overall survival (OS) were compared between the groups with and without ECE using univariate Kaplan-Meier and multivariate Cox regression survival analyses...
November 2017: Oral Oncology
Matthew C Ward, Chirag Shah, David J Adelstein, Jessica L Geiger, Jacob A Miller, Shlomo A Koyfman, Mendel E Singer
OBJECTIVE: Nivolumab is the first drug to demonstrate a survival benefit for platinum-refractory recurrent or metastatic head and neck cancer. We performed a cost-utility analysis to assess the economic value of nivolumab as compared to alternative standard agents in this context. MATERIALS AND METHODS: Using data from the CheckMate 141 trial, we constructed a Markov simulation model from the US payer's perspective to evaluate the cost-effectiveness of nivolumab compared to physician choice of either cetuximab, methotrexate or docetaxel...
November 2017: Oral Oncology
Nicole C Schmitt, Hyunseok Kang, Arun Sharma
Salivary duct carcinoma (SDC) is a rare, aggressive salivary malignancy that is often diagnosed at an advanced stage. Previously, little was known about outcomes of this disease due to its rarity. In the past several years, much has been learned about salivary duct carcinoma after publication of outcomes from several large single-institution series and national database searches. Recent studies of genomic alterations have helped elucidate the biology and pathogenesis of this aggressive disease. Here we review outcomes of the disease, effects of treatment, prognostic factors, and genomic alterations in SDC...
November 2017: Oral Oncology
Jing-Lin Mi, Bin Zhang, Yu-Fei Pan, Yi-Xin Su, Jin-Fang Fan, Shu-Fang Liao, Xiao-Li Qin, Da-Cheng Yao, Hua-Ying Tang, Wei Jiang
OBJECTIVES: The efficacy of various chemotherapy regimens in nasopharyngeal carcinoma (NPC) remains under debate. We compared the efficacy and toxicity of a taxane-based regimen and regimen including fluorouracil in NPC. MATERIALS AND METHODS: Eight-hundred and six patients with stage II-IVB NPC from four institutions in China were pair-matched (1:1 ratio) to the cisplatin plus fluorouracil (PF) group or cisplatin plus taxanes (TP) group using eight clinical factors...
November 2017: Oral Oncology
Richard Dirven, Ardalan Ebrahimi, Nikolaus Moeckelmann, Carsten Erich Palme, Ruta Gupta, Jonathan Clark
OBJECTIVES: The primary aim of this study is to compare the effect of using tumor thickness versus depth of invasion (DOI) to determine the 8th edition AJCC T-category on survival in a large cohort of OSCC. MATERIALS AND METHODS: A retrospective cohort study of patients whose clinicopathologic information had been collected prospectively into a dedicated head and neck database. 927 patients with oral SCC were identified in this cohort, with the final study population including 456 patients with complete information on DOI, tumor thickness, T and N staging and follow-up...
November 2017: Oral Oncology
Mario Turri-Zanoni, Roberta Maragliano, Paolo Battaglia, Marta Giovannardi, Paolo Antognoni, Davide Lombardi, Maria Laura Morassi, Ernesto Pasquini, Paolo Tarchini, Sofia Asioli, Maria Pia Foschini, Fausto Sessa, Piero Nicolai, Paolo Castelnuovo, Stefano La Rosa
OBJECTIVES: To provide a comprehensive review of the clinical and histopathological features of olfactory neuroblastoma (ONB) and other sinonasal neuroendocrine neoplasms (NENs), in order to refine diagnostic criteria, analyze treatment outcomes, and identify prognostic factors. METHODS: Data from an Italian multi-institutional database were analyzed. Patients were treated surgically via a minimally-invasive endoscopic approach followed by adjuvant radiotherapy or radiochemotherapy...
November 2017: Oral Oncology
Matthew Old
No abstract text is available yet for this article.
November 2017: Oral Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"